Nicole Kinnane1. 1. Peter MacCallum Cancer Institute, Locked Bag 1, A'Beckett Street, Melbourne, Victoria 8006, Australia. Nicole.Kinnane@petermac.org
Abstract
OBJECTIVES: Malignant bone disease can cause clinically relevant skeletal morbidity that negatively affects quality of life. The prevalence and consequences of skeletal-related events (SREs) resulting from bone metastases, and the effects of bone metastasis therapies will be discussed. METHODS: The burden of bone disease was researched through PubMed and the proceedings of international oncology meetings. RESULTS: Malignant bone disease is a potentially devastating condition that is prevalent in patients with advanced cancers. Most patients with bone metastases experience at least 1 SRE, which may reduce survival and add considerably to healthcare costs. Bone pain, the most common source of severe pain in these patients, can often be managed with analgesics or radiotherapy. However, treatment may be difficult because of associated side effects. Bisphosphonates palliate bone pain and can treat the underlying cause of the symptoms: malignant osteolysis. Preventing or delaying the onset of SREs is crucial because patients with an SRE have an increased risk of additional SREs, thereby reducing quality of life. CONCLUSIONS: Metastatic bone disease is a tremendous burden on patients and society. Supportive therapy with zoledronic acid has shown benefits for patients with bone metastases by delaying the onset and reducing the incidence of SREs, thus preserving patients' quality of life and functional independence.
OBJECTIVES:Malignant bone disease can cause clinically relevant skeletal morbidity that negatively affects quality of life. The prevalence and consequences of skeletal-related events (SREs) resulting from bone metastases, and the effects of bone metastasis therapies will be discussed. METHODS: The burden of bone disease was researched through PubMed and the proceedings of international oncology meetings. RESULTS:Malignant bone disease is a potentially devastating condition that is prevalent in patients with advanced cancers. Most patients with bone metastases experience at least 1 SRE, which may reduce survival and add considerably to healthcare costs. Bone pain, the most common source of severe pain in these patients, can often be managed with analgesics or radiotherapy. However, treatment may be difficult because of associated side effects. Bisphosphonatespalliate bone pain and can treat the underlying cause of the symptoms: malignant osteolysis. Preventing or delaying the onset of SREs is crucial because patients with an SRE have an increased risk of additional SREs, thereby reducing quality of life. CONCLUSIONS:Metastatic bone disease is a tremendous burden on patients and society. Supportive therapy with zoledronic acid has shown benefits for patients with bone metastases by delaying the onset and reducing the incidence of SREs, thus preserving patients' quality of life and functional independence.
Authors: Ragnhild Habberstad; M J Hjermstad; C Brunelli; S Kaasa; M I Bennett; K Pardon; P Klepstad Journal: Support Care Cancer Date: 2018-08-13 Impact factor: 3.603
Authors: Michael Gnant; Marija Balic; Edgar Petru; Wolfgang Raunik; Christian F Singer; Guenther G Steger; Ingeborg M Watzke; Thomas Brodowicz Journal: Breast Care (Basel) Date: 2012-04-24 Impact factor: 2.860
Authors: Rodica Anghel; Alexander Bachmann; Meral Bekşac; Thomas Brodowicz; Jindřich Finek; Radko Komadina; Krzysztof Krzemieniecki; Istvan Lang; Jozef Marencak; Roger von Moos; Martin Pecherstorfer; Tamara Rordorf; Damir Vrbanec; Christoph Zielinski Journal: Wien Klin Wochenschr Date: 2013-07-06 Impact factor: 1.704
Authors: Joseph E Burns; Jianhua Yao; Tatjana S Wiese; Hector E Muñoz; Elizabeth C Jones; Ronald M Summers Journal: Radiology Date: 2013-02-28 Impact factor: 11.105
Authors: Prue Cormie; Daniel A Galvão; Nigel Spry; David Joseph; Dennis R Taaffe; Robert U Newton Journal: Support Care Cancer Date: 2014-01-15 Impact factor: 3.603